A precision-oncology biotech emerging from stealth with a $100 million Series A and an epitope-level targeting approach to antibody-drug conjugates designed to differentiate at the antibody-selection ...

CAMBRIDGE, Mass. and BASEL, Switzerland, June 04, 2026 (GLOBE NEWSWIRE) -- Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Stipple Bio, Inc., a ...

- Stipple Bio’s Pointillist Platform identifies tumor-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC ...

— Stipple Bio’s Pointillist Platform identifies tumor-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC ...

Abstract: This letter is part of a three-part tutorial that focuses on joint radar-communication system design for vehicular networks. As Part I of the tutorial, this letter reviews the fundamental ...

Java developers absolutely must learn Maven. Maven is the most popular and pervasive build tool in the Java world. Even if you don't use Maven directly, alternatives such as Gradle, Jenkins or Ivy ...

Stipple Bio专注于开发表位靶向癌症疗法，主要产品是Pointillist 平台及核心ADC候选药物 STP-100，应用于实体瘤与血液肿瘤的精准靶向治疗领域。近日，Stipple Bio获得种子轮融资，OMX Ventures、Emerson Collective、Andreessen Horowitz-a16z投资。

Stipple Bio专注于开发表位靶向癌症疗法，主要产品是Pointillist 平台及核心ADC候选药物 STP-100，应用于实体瘤与血液肿瘤的精准靶向治疗领域。近日，Stipple Bio获得1亿美元A轮融资，Nextech Invest、RA Capital Management、Andreessen Horowitz-a16z联合领投，GordonMD Global ...

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the ...